1147558-27-7

Basic information

• Product Name: 3-chloro-4-(6-chloro-5-fluoropyrimidin-4-ylamino)benzonitrile
• Synonyms: 3-chloro-4-(6-chloro-5-fluoropyrimidin-4-ylamino)benzonitrile;3-Chloro-4-[(6-chloro-5-fluoro-4-pyrimidinyl)amino]benzonitrile
• CAS NO: 1147558-27-7
• Molecular Formula: C11H5Cl2FN4
• Molecular Weight: 283.0886032
• Mol File: 1147558-27-7.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Density: 1.56
• CAS DataBase Reference: 3-chloro-4-(6-chloro-5-fluoropyrimidin-4-ylamino)benzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 3-chloro-4-(6-chloro-5-fluoropyrimidin-4-ylamino)benzonitrile(1147558-27-7)
• EPA Substance Registry System: 3-chloro-4-(6-chloro-5-fluoropyrimidin-4-ylamino)benzonitrile(1147558-27-7)

Safety Data

• Hazardous Substances Data: 1147558-27-7(Hazardous Substances Data)

Usage

General Description

3-chloro-4-(6-chloro-5-fluoropyrimidin-4-ylamino)benzonitrile is a chemical compound with the molecular formula C13H6Cl2F1N5. It is a derivative of benzonitrile and contains chloro and fluoro substitutions on the pyrimidine ring. 3-chloro-4-(6-chloro-5-fluoropyrimidin-4-ylamino)benzonitrile is commonly used as a building block in the synthesis of pharmaceuticals and agricultural products. It may also have potential applications in the development of new drugs and agrochemicals. The presence of the chloro and fluoro groups in the molecule makes it a valuable starting material for creating a wide range of diverse chemical compounds with different properties and functions.

Upstream product

• 213265-83-9 4,6-dichloro-5-fluoropyrimidine 
• 21803-75-8 4-amino-3-chlorobenzonitrile 

Downstream Products

• 1147556-26-0 tert-butyl (1R,5S,9r)-9-((6-((2-chloro-4-cyanophenyl)amino)-5-fluoropyrimidin-4-yl)oxy)-3-oxa-7-azabicyclo[3.3.1]nonane-7-carboxylate 

Relevant articles and documents

Discovery of MK-8282 as a Potent G-Protein-Coupled Receptor 119 Agonist for the Treatment of Type 2 Diabetes

The ever-growing prevalence of type 2 diabetes in the world has necessitated an urgent need for multiple orally effective agents that can regulate glucose homeostasis with a concurrent reduction in body weight. G-Protein coupled receptor 119 (GPR119) is a GPCR target at which agonists have demonstrated glucose-dependent insulin secretion and shows beneficial effects on glycemic control. Herein, we describe our efforts leading to the identification of a potent, oral GPR-119 agonist, MK-8282, which shows improved glucose tolerance in multiple animal models and has excellent off-target profile. The key design elements in the compounds involved a combination of a fluoro-pyrimidine and a conformationally constrained bridged piperidine to impart good potency and efficacy.